48123-4 |
Somatotropin^15M pre dose arginine+insulin |
ACnc |
Ser/Plas |
Pt |
Qn |
|
|
ACTIVE |
Somatotropin [Units/volume] in Serum or Plasma --15 minutes pre dose arginine+insulin |
|
MIN |
DefinitionDescription |
|
|
mIU/L |
|
|
|
|
|
|
CHAL |
|
48123-4 |
|
|
|
|
Observation |
|
|
|
0 |
GH 15M pre Arg+Ins SerPl-aCnc |
|
|
|
N |
|
15M pre arg; 15M pre Arg+Ins; Arbitrary Concentration; Arg; Before; CHEMISTRY.CHALLENGE TESTING; Endocrine; Endocrinology; GH; Growth hormone; HGH; HUM; Human growth hormone; Humulin; IH7; Insul; Lente; NPH; Pl; Plasma; Plsm; Point in time; pre Arg; pre dose Arg+Ins; QNT; Quan; Quant; Quantitative; Random; Semilente; SerP; SerPl; SerPlas; Serum; Serum or plasma; Sliding; Somatotropic hormone; SR; STH; Ultralente |
2.7 |
2.21 |
|
|
|
|
|
|
|
m[IU]/L |
|
|
|
0 |
48124-2 |
Somatotropin^15M pre dose glucagon |
ACnc |
Ser/Plas |
Pt |
Qn |
|
|
ACTIVE |
Somatotropin [Units/volume] in Serum or Plasma --15 minutes pre dose glucagon |
|
MIN |
DefinitionDescription |
|
|
mIU/L |
|
|
|
|
|
|
CHAL |
|
48124-2 |
|
|
|
|
Observation |
|
|
|
0 |
GH 15M pre Gc SerPl-aCnc |
|
|
|
N |
|
15M pre Gc; Arbitrary Concentration; Before; CHEMISTRY.CHALLENGE TESTING; Endocrine; Endocrinology; GH; Growth hormone; HGF; HGH; Human growth hormone; Hyperglycemic factor; Pl; Plasma; Plsm; Point in time; pre Gc; QNT; Quan; Quant; Quantitative; Random; SerP; SerPl; SerPlas; Serum; Serum or plasma; Somatotropic hormone; SR; STH |
2.7 |
2.21 |
|
|
|
|
|
|
|
m[IU]/L |
|
|
|
0 |
48125-9 |
Somatotropin^15M pre dose insulin IV |
ACnc |
Ser/Plas |
Pt |
Qn |
|
|
ACTIVE |
Somatotropin [Units/volume] in Serum or Plasma --15 minutes pre dose insulin IV |
|
MIN |
DefinitionDescription |
|
|
mIU/L |
|
|
|
|
|
|
CHAL |
|
48125-9 |
|
|
|
|
Observation |
|
|
|
0 |
GH 15M pre Ins IV SerPl-aCnc |
|
|
|
N |
|
15M pre Ins IV; Arbitrary Concentration; Before; CHEMISTRY.CHALLENGE TESTING; Endocrine; Endocrinology; GH; Growth hormone; HGH; HUM; Human growth hormone; Humulin; IH7; Insul; Lente; NPH; Pl; Plasma; Plsm; Point in time; pre Ins IV; QNT; Quan; Quant; Quantitative; Random; Semilente; SerP; SerPl; SerPlas; Serum; Serum or plasma; Sliding; Somatotropic hormone; SR; STH; Ultralente |
2.7 |
2.21 |
|
|
|
|
|
|
|
m[IU]/L |
|
|
|
0 |
48126-7 |
Somatotropin^15M pre dose ornithine |
ACnc |
Ser/Plas |
Pt |
Qn |
|
|
ACTIVE |
Somatotropin [Units/volume] in Serum or Plasma --15 minutes pre dose ornithine |
|
MIN |
DefinitionDescription |
|
|
mIU/L |
|
|
|
|
|
|
CHEM |
|
48126-7 |
|
|
|
|
Observation |
|
|
|
0 |
GH 15M pre Orn SerPl-aCnc |
|
|
|
N |
|
15M pre Orn; Arbitrary Concentration; Before; Chemistry; Endocrine; Endocrinology; GH; Growth hormone; HGH; Human growth hormone; Orn; Pl; Plasma; Plsm; Point in time; pre Orn; QNT; Quan; Quant; Quantitative; Random; SerP; SerPl; SerPlas; Serum; Serum or plasma; Somatotropic hormone; SR; STH |
2.7 |
2.21 |
|
|
|
|
|
|
|
m[IU]/L |
|
|
|
0 |
48127-5 |
Somatotropin^15M pre dose TRH |
ACnc |
Ser/Plas |
Pt |
Qn |
|
|
ACTIVE |
Somatotropin [Units/volume] in Serum or Plasma --15 minutes pre dose TRH |
|
MIN |
DefinitionDescription |
|
|
mIU/L |
|
|
|
|
|
|
CHAL |
|
48127-5 |
|
|
|
|
Observation |
|
|
|
0 |
GH 15M pre TRH SerPl-aCnc |
|
|
|
N |
|
15M pre TRH; Arbitrary Concentration; Before; CHEMISTRY.CHALLENGE TESTING; Endocrine; Endocrinology; GH; Growth hormone; HGH; Human growth hormone; Pl; Plasma; Plsm; Point in time; pre TRH; QNT; Quan; Quant; Quantitative; Random; SerP; SerPl; SerPlas; Serum; Serum or plasma; Somatotropic hormone; SR; STH |
2.7 |
2.21 |
|
|
|
|
|
|
|
m[IU]/L |
|
|
|
0 |
48128-3 |
Somatotropin^1H post dose arginine+insulin |
ACnc |
Ser/Plas |
Pt |
Qn |
|
|
ACTIVE |
Somatotropin [Units/volume] in Serum or Plasma --1 hour post dose arginine+insulin |
|
MIN |
DefinitionDescription |
|
|
mIU/L |
|
|
|
|
|
|
CHAL |
|
48128-3 |
|
|
|
|
Observation |
|
|
|
0 |
GH 1h p Arg+Ins SerPl-aCnc |
|
|
|
N |
|
1 hour; 1.0Hr; 1h p Arg; 1h p Arg+Ins; 60 min; 60 minutes; 60M; 60min; After; Arbitrary concentration; Arg; CHEMISTRY.CHALLENGE TESTING; Endocrine; Endocrinology; GH; Growth hormone; HGH; HUM; Human growth hormone; Humulin; IH7; Insul; Lente; NPH; p dose; Pl; Plasma; Plsm; Point in time; PST; QNT; Quan; Quant; Quantitative; Random; Semilente; SerP; SerPl; SerPlas; Serum; Serum or plasma; Sliding; Somatotropic hormone; SR; STH; Ultralente |
2.7 |
2.21 |
|
|
|
|
|
|
|
m[IU]/L |
|
|
|
0 |
48129-1 |
Somatotropin^30M pre dose betaxolol+glucagon |
ACnc |
Ser/Plas |
Pt |
Qn |
|
|
ACTIVE |
Somatotropin [Units/volume] in Serum or Plasma --30 minutes pre dose betaxolol+glucagon |
|
MIN |
DefinitionDescription |
|
|
mIU/L |
|
|
|
|
|
|
CHAL |
|
48129-1 |
|
|
|
|
Observation |
|
|
|
0 |
GH 30M Pre betaxolol+Gc SerPl-aCnc |
|
|
|
N |
|
30M pre betaxolol; 30M Pre betaxolol+Gc; Arbitrary Concentration; Before; CHEMISTRY.CHALLENGE TESTING; Endocrine; Endocrinology; GH; Growth hormone; HGF; HGH; Human growth hormone; Hyperglycemic factor; Pl; Plasma; Plsm; Point in time; pre betaxolol; pre dose betaxolol+Gc; QNT; Quan; Quant; Quantitative; Random; SerP; SerPl; SerPlas; Serum; Serum or plasma; Somatotropic hormone; SR; STH |
2.7 |
2.21 |
|
|
|
|
|
|
|
m[IU]/L |
|
|
|
0 |
4813-2 |
HLA-B16 |
PrThr |
Bld/Tiss |
Pt |
Ord |
|
|
ACTIVE |
HLA-B16 [Presence] |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
HLA |
|
4813-2 |
|
|
|
|
Observation |
|
|
|
0 |
HLA-B16 Ql |
|
|
|
|
|
Blood; Genetics; Heredity; Heritable; HLA ANTIGEN; Human Leukocyte Antigen; Inherited; Ordinal; Point in time; PR; QL; Qual; Qualitative; Random; Screen; Tissue; Tissue, unspecified; WB; Whole blood; Whole blood or Tissue |
2.56 |
1 |
|
|
|
|
|
|
|
|
|
|
This test is commonly performed on cells found in saliva and buccal swabs as well as blood specimens. Changed specimen from 'Bld' to 'Bld/Tiss' to represent both specimen types.; The PrThr property is used for LOINC terms whose results are reported using an ordered categorical scale, regardless of whether or not an internal threshold was used to make that determination. This change was approved by the Laboratory LOINC Committee in June 2016. |
0 |
48130-9 |
Somatotropin^30M pre dose propranolol+glucagon |
ACnc |
Ser/Plas |
Pt |
Qn |
|
|
ACTIVE |
Somatotropin [Units/volume] in Serum or Plasma --30 minutes pre dose propranolol+glucagon |
|
MIN |
DefinitionDescription |
|
|
mIU/L |
|
|
|
|
|
|
CHAL |
|
48130-9 |
|
|
|
|
Observation |
|
|
|
0 |
GH 30M pre propranolol+Gc SerPl-aCnc |
|
|
|
N |
|
30M pre propranolol+Gc; Arbitrary Concentration; Before; CHEMISTRY.CHALLENGE TESTING; Endocrine; Endocrinology; GH; Growth hormone; HGF; HGH; Human growth hormone; Hyperglycemic factor; Inderal; Pl; Plasma; Plsm; Point in time; pre dose propranolol+Gc; QNT; Quan; Quant; Quantitative; Random; SerP; SerPl; SerPlas; Serum; Serum or plasma; Somatotropic hormone; SR; STH |
2.7 |
2.21 |
|
|
|
|
|
|
|
m[IU]/L |
|
|
|
0 |
48131-7 |
Somatotropin^30M pre dose TRH |
ACnc |
Ser/Plas |
Pt |
Qn |
|
|
ACTIVE |
Somatotropin [Units/volume] in Serum or Plasma --30 minutes pre dose TRH |
|
MIN |
DefinitionDescription |
|
|
mIU/L |
|
|
|
|
|
|
CHAL |
|
48131-7 |
|
|
|
|
Observation |
|
|
|
0 |
GH 30M pre TRH SerPl-aCnc |
|
|
|
N |
|
30M pre TRH; Arbitrary Concentration; Before; CHEMISTRY.CHALLENGE TESTING; Endocrine; Endocrinology; GH; Growth hormone; HGH; Human growth hormone; Pl; Plasma; Plsm; Point in time; pre TRH; QNT; Quan; Quant; Quantitative; Random; SerP; SerPl; SerPlas; Serum; Serum or plasma; Somatotropic hormone; SR; STH |
2.7 |
2.21 |
|
|
|
|
|
|
|
m[IU]/L |
|
|
|
0 |
48132-5 |
Xylitol/Creatinine |
SRto |
Urine |
Pt |
Qn |
|
|
ACTIVE |
Xylitol/Creatinine [Molar ratio] in Urine |
|
MIN |
DefinitionDescription |
|
|
umol/mmol creatinine |
|
|
|
|
|
|
DRUG/TOX |
|
48132-5 |
|
|
|
|
Both |
|
|
|
0 |
Xylitol/Creat Ur-sRto |
|
|
|
N |
|
CR; Crea; Creat; DRUG/TOXICOLOGY; Drugs; Point in time; QNT; Quan; Quant; Quantitative; Random; Scrto; Substance concentration ratio; Substance ratio; UA; UCr; UR; Urn |
2.7 |
2.21 |
|
|
|
|
|
|
|
umol/mmol{creat} |
|
|
|
0 |
48133-3 |
3-Oxovalerate |
SCnc |
Plas |
Pt |
Qn |
|
|
ACTIVE |
3-Oxovalerate [Moles/volume] in Plasma |
|
MIN |
DefinitionDescription |
|
|
umol/L |
|
|
|
|
|
|
CHEM |
|
48133-3 |
|
|
|
|
Both |
|
|
|
0 |
3-Oxovalerate Plas-sCnc |
|
|
|
N |
|
3-oxovaleric acid; Chemistry; III; Level; Pl; Plasma; Plsm; Point in time; QNT; Quan; Quant; Quantitative; Random; Substance concentration |
2.7 |
2.21 |
|
|
|
|
|
|
|
umol/L |
|
|
|
0 |
48134-1 |
Alanine aminotransferase.macromolecular |
CCnc |
Ser/Plas |
Pt |
Qn |
|
|
ACTIVE |
Alanine aminotransferase.macromolecular [Enzymatic activity/volume] in Serum or Plasma |
|
MIN |
DefinitionDescription |
|
|
arb U/L |
|
|
|
|
|
|
CHEM |
|
48134-1 |
|
|
|
|
Both |
|
|
|
0 |
ALT Macro SerPl-cCnc |
|
|
|
N |
|
Ala; Alanine transaminase; ALAT; Alpha alanine; ALT; ALT Macro; Catalytic Concentration; Chemistry; Glutamic-pyruvic transferase; Hepatology; L-alanine; Liver; Pl; Plasma; Plsm; Point in time; QNT; Quan; Quant; Quantitative; Random; SerP; SerPl; SerPlas; Serum; Serum or plasma; SGPT; SR |
2.73 |
2.21 |
|
|
|
|
|
|
|
U/L |
|
|
|
0 |
48135-8 |
Acadesine |
PrThr |
Urine |
Pt |
Ord |
|
|
ACTIVE |
Acadesine [Presence] in Urine |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
DRUG/TOX |
|
48135-8 |
|
|
|
|
Both |
|
|
|
0 |
Acadesine Ur Ql |
|
|
|
N |
|
5-amino imidazole carboxamide riboside; AICAR; AICA-riboside; Amino imidazole carboxamide riboside; Aminoimidazole carboxamide riboside; DRUG/TOXICOLOGY; Drugs; Ordinal; Point in time; PR; QL; Qual; Qualitative; Random; Screen; UA; UR; Urn |
2.56 |
2.21 |
|
|
|
|
|
|
|
|
|
|
The Property has been changed from ACnc to reflect the new model for ordinal terms where results are based on a cut-off value.; The PrThr property is used for LOINC terms whose results are reported using an ordered categorical scale, regardless of whether or not an internal threshold was used to make that determination. This change was approved by the Laboratory LOINC Committee in June 2016. |
0 |
48136-6 |
Aspartate aminotransferase.macromolecular |
CCnc |
Ser/Plas |
Pt |
Qn |
|
|
ACTIVE |
Aspartate aminotransferase.macromolecular [Enzymatic activity/volume] in Serum or Plasma |
|
MIN |
DefinitionDescription |
|
|
arb U/L |
|
|
|
|
|
|
CHEM |
|
48136-6 |
|
|
|
|
Both |
|
|
|
0 |
AST Macro SerPl-cCnc |
|
|
|
N |
|
Asp; Aspartate amino transferase; Aspartate transaminase; Aspartic acid; AST; AST Macro; Catalytic Concentration; Chemistry; Glutamic oxaloacetic transaminase; Hepatology; Liver; Pl; Plasma; Plsm; Point in time; QNT; Quan; Quant; Quantitative; Random; SerP; SerPl; SerPlas; Serum; Serum or plasma; SGOT; SR |
2.73 |
2.21 |
|
|
|
|
|
|
|
U/L |
|
|
|
0 |
48137-4 |
4,5-Dihydroxyhexanoate/Creatinine |
SRto |
Urine |
Pt |
Qn |
|
|
ACTIVE |
4,5-Dihydroxyhexanoate/Creatinine [Molar ratio] in Urine |
|
MIN |
DefinitionDescription |
|
|
umol/mmol creatinine |
|
|
|
|
|
|
CHEM |
|
48137-4 |
|
|
|
|
Both |
|
|
|
0 |
4,5-DiOH-hexanoate/Creat Ur-sRto |
|
|
|
N |
|
4,5-DHHA; 4,5-dihydroxyhexanoic acid; 4,5-DiOH-hexanoate; Chemistry; CR; Crea; Creat; Point in time; QNT; Quan; Quant; Quantitative; Random; Scrto; Solerol; Substance concentration ratio; Substance ratio; UA; UCr; UR; Urn |
2.7 |
2.21 |
|
|
|
|
|
|
|
umol/mmol{creat} |
|
|
|
0 |
48138-2 |
Enolase.neuron specific |
MCnc |
Ser/Plas |
Pt |
Qn |
RIA |
|
ACTIVE |
Enolase.neuron specific [Mass/volume] in Serum or Plasma by Radioimmunoassay (RIA) |
|
MIN |
DefinitionDescription |
|
|
ug/L |
|
|
|
|
|
|
CHEM |
|
48138-2 |
|
RIA |
|
|
Both |
|
|
|
0 |
NSE SerPl RIA-mCnc |
|
|
|
N |
|
Chemistry; ENO2; enolase 2; Gamma-enolase; Level; Mass concentration; NSE; Phosphopyruvate dehydratase; Phosphopyruvate hydratase.gamma subunit; Pl; Plasma; Plsm; Point in time; QNT; Quan; Quant; Quantitative; RADIOIMMUNOASSAY; Random; SerP; SerPl; SerPlas; Serum; Serum or plasma; Spec; SR; Tumor marker |
2.7 |
2.21 |
|
|
|
|
|
|
|
ug/L |
|
|
|
0 |
48139-0 |
Erythro-4,5-Dihydroxyhexanoate/Creatinine |
SRto |
Urine |
Pt |
Qn |
|
|
ACTIVE |
Erythro-4,5-Dihydroxyhexanoate/Creatinine [Molar ratio] in Urine |
|
MIN |
DefinitionDescription |
|
|
umol/mmol creatinine |
|
|
|
|
|
|
CHEM |
|
48139-0 |
|
|
|
|
Both |
|
|
|
0 |
Erythro-4,5-DHA/Creat Ur-sRto |
|
|
|
N |
|
4,5-DHHA; 4,5-dihydroxyhexanoic acid; 4,5-DiOH-hexanoate; Chemistry; CR; Crea; Creat; Erythro-4,5-DHA; Erythro-4,5-dihydroxyhexanoic acid; Point in time; QNT; Quan; Quant; Quantitative; Random; Scrto; Solerol; Substance concentration ratio; Substance ratio; UA; UCr; UR; Urn |
2.7 |
2.21 |
|
|
|
|
|
|
|
umol/mmol{creat} |
|
|
|
0 |
4814-0 |
HLA-B17 |
PrThr |
Bld/Tiss^Donor |
Pt |
Ord |
|
|
ACTIVE |
HLA-B17 [Presence] in Donor |
|
MAJ |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
HLA |
|
4814-0 |
|
|
|
|
Observation |
|
|
|
0 |
HLA-B17 Donr Ql |
|
|
|
|
|
Blood; Donr; Genetics; Heredity; Heritable; HLA ANTIGEN; Human Leukocyte Antigen; Inherited; Ordinal; Point in time; PR; QL; Qual; Qualitative; Random; Screen; Tissue; Tissue, unspecified; WB; Whole blood; Whole blood or Tissue |
2.56 |
1 |
|
|
|
|
|
|
|
|
|
|
This test is commonly performed on cells found in saliva and buccal swabs as well as blood specimens. Changed specimen from 'Bld^donor' to 'Bld/Tiss^donor' to represent both specimen types.; The PrThr property is used for LOINC terms whose results are reported using an ordered categorical scale, regardless of whether or not an internal threshold was used to make that determination. This change was approved by the Laboratory LOINC Committee in June 2016. |
0 |
48140-8 |
Erythro-4-Deoxytetronate/Creatinine |
SRto |
Urine |
Pt |
Qn |
|
|
ACTIVE |
Erythro-4-Deoxytetronate/Creatinine [Molar ratio] in Urine |
|
MIN |
DefinitionDescription |
|
|
umol/mmol creatinine |
|
|
|
|
|
|
CHEM |
|
48140-8 |
|
|
|
|
Both |
|
|
|
0 |
Erythro-4-deoxytetronate/Creat Ur-sRto |
|
|
|
N |
|
Chemistry; CR; Crea; Creat; Erythro-4-deoxytetronic acid; Point in time; QNT; Quan; Quant; Quantitative; Random; Scrto; Substance concentration ratio; Substance ratio; UA; UCr; UR; Urn |
2.7 |
2.21 |
|
|
|
|
|
|
|
umol/mmol{creat} |
|
|
|
0 |
48141-6 |
Ferritin |
EntMass |
RBC |
Pt |
Qn |
|
|
ACTIVE |
Ferritin [Entitic mass] in Red Blood Cells |
|
MIN |
DefinitionDescription |
|
|
/cell |
|
|
|
|
|
|
CHEM |
|
48141-6 |
|
|
|
|
Both |
|
|
|
0 |
Ferritin RBC Qn |
|
|
|
N |
|
Chemistry; Entitic mass; Erythrocytes; Ferr; Point in time; QNT; Quan; Quant; Quantitative; Random; Red blood cells; Red blood corpusles |
2.7 |
2.21 |
|
|
|
|
|
|
|
/{cell} |
|
|
|
0 |
48142-4 |
Indole-3-Acetate/Creatinine |
SRto |
Urine |
Pt |
Qn |
|
|
ACTIVE |
Indole-3-Acetate/Creatinine [Molar ratio] in Urine |
|
MIN |
DefinitionDescription |
|
|
umol/mmol creatinine |
|
|
|
|
|
|
CHEM |
|
48142-4 |
|
|
|
|
Both |
|
|
|
0 |
Indole-3-acetate/Creat Ur-sRto |
|
|
|
N |
|
Acetic acid; Chemistry; CR; Crea; Creat; Ethanoate; Ethanoic acid; IA; IAA; III; Indole-3-acetic acid; Indoleacetate; Indoleacetic acid; Point in time; QNT; Quan; Quant; Quantitative; Random; Scrto; Substance concentration ratio; Substance ratio; UA; UCr; UR; Urn |
2.7 |
2.21 |
|
|
|
|
|
|
|
umol/mmol{creat} |
|
|
|
0 |
48143-2 |
LDL.oxidized Ab |
ACnc |
Ser |
Pt |
Qn |
|
|
ACTIVE |
LDL.oxidized Ab [Units/volume] in Serum |
|
MIN |
DefinitionDescription |
|
|
m arb U/mL |
|
|
|
|
|
|
SERO |
|
48143-2 |
|
|
|
|
Both |
|
|
|
0 |
LDL.oxidized Ab Ser-aCnc |
|
|
|
N |
|
ABS; Aby; Antby; Anti; Antibodies; Antibody; Arbitrary concentration; Autoantibodies; Autoantibody; Cardio; Cardiology; Heart Disease; oxLDL; Point in time; QNT; Quan; Quant; Quantitative; Random; Serology; Serum; SR |
2.73 |
2.21 |
|
|
|
|
|
|
|
m[arb'U]/mL |
|
|
|
0 |
48144-0 |
Mannose |
PrThr |
Urine |
Pt |
Ord |
|
|
ACTIVE |
Mannose [Presence] in Urine |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
DRUG/TOX |
|
48144-0 |
|
|
|
|
Both |
|
|
|
0 |
Mannose Ur Ql |
|
|
|
N |
|
DRUG/TOXICOLOGY; Drugs; Ordinal; Point in time; PR; QL; Qual; Qualitative; Random; Screen; UA; UR; Urn |
2.56 |
2.21 |
|
|
|
|
|
|
|
|
|
|
The Property has been changed from ACnc to reflect the new model for ordinal terms where results are based on a cut-off value.; The PrThr property is used for LOINC terms whose results are reported using an ordered categorical scale, regardless of whether or not an internal threshold was used to make that determination. This change was approved by the Laboratory LOINC Committee in June 2016. |
0 |
48145-7 |
Mevalonolactone/Creatinine |
SRto |
Urine |
Pt |
Qn |
|
|
ACTIVE |
Mevalonolactone/Creatinine [Molar ratio] in Urine |
|
MIN |
DefinitionDescription |
|
|
umol/mmol creatinine |
|
|
|
|
|
|
CHEM |
|
48145-7 |
|
|
|
|
Both |
|
|
|
0 |
Mevalonolactone/Creat Ur-sRto |
|
|
|
N |
|
Chemistry; CR; Crea; Creat; Mevalonic acid lactone; MVL; Point in time; QNT; Quan; Quant; Quantitative; Random; Scrto; Substance concentration ratio; Substance ratio; UA; UCr; UR; Urn |
2.7 |
2.21 |
|
|
|
|
|
|
|
umol/mmol{creat} |
|
|
|
0 |